A study of Tyverb/Tykerb (lapatinib ditosylate), from Glaxo Smith Kline, in combination with chemotherapy in patients with HER2-positive advanced Gastric...
GlaxoSmithKline has announced that the Phase III study of two anti-HER2 agents, Tykerb/Tyverb (lapatinib) and trastuzumab, did not meet the...
Adding Tyverb/Tykerb(lapatinib), from Glaxo Smith Kline, to Herceptin (trastuzumab) was more effective than single-drug treatment with either drug in eliminating...
In the Phase III LUX-BREAST 1 study Giotrif (afatinib) plus vinorelbine (The Boehringer combination) showed a similar progression free survival...
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center...
GSK presented results from the TEACH study to the 2011 CRTC-AACR San Antonio Breast Cancer Symposium. TEACH is a randomised,...
Novartis has announced that it has completed a series of transactions with GlaxoSmithKline plc (GSK), including the acquisition of certain...